| Number of | Percent with outcome | |||||
|---|---|---|---|---|---|---|
| Outcome | Studies | Participants | Gabapentin | Placebo | Risk ratio (95% CI) | NNH (95% CI) |
| Withdrawal due to adverse events | 17 | 3022 | 12 | 8 | 1.4 (1.1 to 1.7) | 32 (19 to 100) |
| Withdrawal - all-cause | 17 | 3063 | 20 | 19 | 1.1 (0.9 to 1.2) | Not calculated |
| At least one adverse event | 11 | 2356 | 66 | 51 | 1.3 (1.2 to 1.4) | 6.6 (5.3 to 9.0) |
| Serious adverse event | 14 | 2702 | 4.0 | 3.2 | 1.3 (0.9 to 2.0) | Not calculated |
| Somnolence/drowsiness | 16 | 2800 | 16 | 5 | 3.2 (2.5 to 4.2) | 9.2 (7.7 to 12) |
| Dizziness | 16 | 3150 | 21 | 7 | 3.2 (2.6 to 4.1) | 7.0 (6.1 to 8.4) |
| Peripheral oedema | 9 | 2042 | 8.2 | 2.9 | 3.4 (2.1 to 5.3) | 19 (14 to 29) |
| Ataxia/gait disturbance | 5 | 544 | 8.8 | 1.2 | 4.5 (1.9 to 11) | 13 (9 to 24) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.